Home/Publication/Lilly Asia, Qiming, HongShan et al Double Down on Cell Therapy Tech
Lilly Asia, Qiming, HongShan et al Double Down on Cell Therapy Tech 

22 Oct 2024

US$ 19.00

Lilly Asia Ventures, Qiming Venture Partners, HongShan and FreesFund, all existing investors of XellSmart ......

Price / article: US$19.00
OR existing subscriber
Related Publications

TPG Inc (TPG) has sold part of its stake in Sai Life Sciences Ltd (Sai Life) and clocked 15 bn rupees (US$173.5 m) in...

Subscribers’ Weekly ending 20 June 2025...

Connect With Us

We love to share Asia PE insights and news from time to time. Drop us your email address if you like to hear from us.

Rest assured that your email address will not be shared, as we hate spams as much as you do.